Floatz logo

18F-Al-NOTA-PRGD2

Carcinoma, Bronchogenic

Wuxi No. 4 People's HospitalPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Carcinoma, Bronchogenic cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nanfang Hospital, Southern Medical University
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3BB
Docetaxel
University of Turin, Italy
Phase 3B
Vinorelbine
University of Turin, Italy
Phase 3B

View all 18 →

Same molecule, other indications

18F-Al-NOTA-PRGD2 is also rated in:

neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
43 / 100
View asset →
lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →